Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Prices Psoriatic Arthritis Drug Otezla At A Discount, But Higher Than Expected

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s approval of oral apremilast paves the way for the company to establish itself in a range of inflammatory conditions.

You may also be interested in...

Earnings Briefs: Biogen, Celgene, Actelion, Cubist

Biogen gains approval for its latest MS treatment in the EU; Celgene pushes ahead with Otezla, despite soft launch; Actelion looking outside PAH for business development; Cubist developing patient access program for Sivextro.

On A Roll With Otezla: Can New Orals And Injectables Crack Psoriasis?

New drugs for psoriasis and psoriatic arthritis have been in the spotlight recently, with new approvals and full pivotal data releases at the recent American Academy of Dermatology meeting. But how the drugs can make inroads in a safety- and cost-cautious market that will soon feature biosimilars remains to be seen.

Celgene Makes A Play For Inflammation & Immunology Stake With Apremilast

With a foundation established in oncology, Celgene is targeting new areas for growth; apremilast, for psoriasis and psoriatic arthritis, is key to the effort.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts